Beclomethasone News and Research

RSS

Beclomethasone is a drug being studied in the treatment of graft-versus-host disease. It belongs to a family of drugs called corticosteroids.

Measuring airway inflammation when diagnosing and treating asthma patients

In this interview, Carol Stonham, the head of a Locality Based FeNO referral service, talks to NewsMed about measuring airway inflammation when diagnosing and treating asthma patients.

From Bedfont® Scientific Ltd 21 Dec 2021

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

'As-needed' treatment OK for children with mild asthma

Children with mild asthma may use two inhalers – one steroid and the other a bronchodilator, when symptoms occur, a new study shows.

19 Aug 2019

Tissue model of Alzheimer's mimics beta-amyloid's effects on blood-brain barrier

Beta-amyloid plaques, the protein aggregates that form in the brains of Alzheimer's patients, disrupt many brain functions and can kill neurons. They can also damage the blood-brain barrier — the normally tight border that prevents harmful molecules in the bloodstream from entering the brain.

13 Aug 2019

Engineers develop tissue model that mimics beta-amyloid's effects on blood-brain barrier

Beta-amyloid plaques, the protein aggregates that form in the brains of Alzheimer's patients, disrupt many brain functions and can kill neurons.

13 Aug 2019

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today.

19 Jul 2016

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.

19 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC.

3 Aug 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

Soligenix closes previously announced registered public offering

25 Dec 2014

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

19 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

8 Sep 2014

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.

2 Sep 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.

7 Aug 2014

Asthma inhalers may suppress children's growth

Corticosteroid drugs that are given by inhalers to children with asthma may suppress their growth, evidence suggests. Two new systematic reviews published in The Cochrane Library focus on the effects of inhaled corticosteroid drugs (ICS) on growth rates.

17 Jul 2014